- Home
- COLL vs ERII Comparison
COLL vs ERII Comparison
Compare COLL & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- ERII
- Stock Information
- Founded
- COLL 2002
- ERII 1992
- Country
- COLL United States
- ERII United States
- Employees
- COLL N/A
- ERII N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- ERII Industrial Machinery/Components
- Sector
- COLL Health Care
- ERII Technology
- Exchange
- COLL Nasdaq
- ERII Nasdaq
- Market Cap
- COLL 910.2M
- ERII 900.2M
- IPO Year
- COLL 2015
- ERII 2008
- Fundamental
- Price
- COLL $30.00
- ERII $15.97
- Analyst Decision
- COLL Strong Buy
- ERII Strong Buy
- Analyst Count
- COLL 5
- ERII 4
- Target Price
- COLL $43.60
- ERII $20.75
- AVG Volume (30 Days)
- COLL 444.8K
- ERII 453.4K
- Earning Date
- COLL 05-08-2025
- ERII 04-30-2025
- Dividend Yield
- COLL N/A
- ERII N/A
- EPS Growth
- COLL 43.56
- ERII 8.11
- EPS
- COLL 1.86
- ERII 0.40
- Revenue
- COLL $631,449,000.00
- ERII $144,948,000.00
- Revenue This Year
- COLL $20.00
- ERII $11.92
- Revenue Next Year
- COLL $3.93
- ERII $11.13
- P/E Ratio
- COLL $16.09
- ERII $39.60
- Revenue Growth
- COLL 11.41
- ERII 12.93
- 52 Week Low
- COLL $27.28
- ERII $12.26
- 52 Week High
- COLL $42.29
- ERII $20.27
- Technical
- Relative Strength Index (RSI)
- COLL 51.96
- ERII 50.78
- Support Level
- COLL $29.01
- ERII $15.52
- Resistance Level
- COLL $30.53
- ERII $16.05
- Average True Range (ATR)
- COLL 0.89
- ERII 0.53
- MACD
- COLL 0.04
- ERII -0.10
- Stochastic Oscillator
- COLL 62.91
- ERII 33.58
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the global reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.